Zura Bio Ltd
NASDAQ:ZURA
Intrinsic Value
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. [ Read More ]
The intrinsic value of one ZURA stock under the Base Case scenario is 1.234 USD. Compared to the current market price of 4.615 USD, Zura Bio Ltd is Overvalued by 73%.
Valuation Backtest
Zura Bio Ltd
Run backtest to discover the historical profit from buying and selling ZURA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Balance Sheet Decomposition
Zura Bio Ltd
Current Assets | 100.8m |
Cash & Short-Term Investments | 99.8m |
Other Current Assets | 1m |
Current Liabilities | 20.3m |
Accounts Payable | 20.2m |
Accrued Liabilities | 111k |
Non-Current Liabilities | 21.2m |
Long-Term Debt | 990k |
Other Non-Current Liabilities | 20.2m |
Earnings Waterfall
Zura Bio Ltd
Revenue
|
0
USD
|
Operating Expenses
|
-63.3m
USD
|
Operating Income
|
-63.3m
USD
|
Other Expenses
|
3.1m
USD
|
Net Income
|
-60.2m
USD
|
Free Cash Flow Analysis
Zura Bio Ltd
USD | |
Free Cash Flow | USD |
ZURA Profitability Score
Profitability Due Diligence
Zura Bio Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Zura Bio Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
ZURA Solvency Score
Solvency Due Diligence
Zura Bio Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Zura Bio Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ZURA Price Targets Summary
Zura Bio Ltd
According to Wall Street analysts, the average 1-year price target for ZURA is 17.51 USD with a low forecast of 10.1 USD and a high forecast of 27.3 USD.
Ownership
ZURA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ZURA Price
Zura Bio Ltd
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -94% |
Market Capitalization | 290.1m USD |
Shares Outstanding | 63 683 800 |
Percentage of Shares Shorted | 1.62% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. The company is headquartered in La Jolla, California. The company went IPO on 2021-07-16. The firm is advancing immunology assets into phase II development programs, including ZB-168 and torudokimab. ZB-168 is an anti-interleukin-7 receptor subunit alpha (IL7Rα) inhibitor that has the potential to impact diseases driven by interleukin-7 (IL7) and thymic stromal lymphopoietin (TSLP) biological pathways. The firm focuses on developing a portfolio of therapeutic indications for ZB-168 that build on existing Phase Ib data in type 1 diabetes demonstrating a safety profile and biological rationale. Torudokimab is a fully human, high affinity monoclonal antibody that neutralizes interleukin-33 (IL33), and is in the phase II clinical development stage.
Contact
IPO
Employees
Officers
The intrinsic value of one ZURA stock under the Base Case scenario is 1.234 USD.
Compared to the current market price of 4.615 USD, Zura Bio Ltd is Overvalued by 73%.